PerkinElmer to Support Expanded Neonatal Screening Program in Saudi Arabia
News Sep 17, 2007
PerkinElmer, Inc. has announced a multi-year agreement with the King Faisal Specialist Hospital and Research Centre in Riyadh, Saudi Arabia, to support its expanded newborn screening program.
Under the terms of the agreement, PerkinElmer will provide instrumentation, reagents, software and screening expertise that will help the King Faisal Hospital double its screening capacity by the end of 2008.
The contract, to be executed through PerkinElmer's regional distributor, HVD Vertriebs Gmbh, will also expand the hospital's program from screening for one disorder to a total of four disorders.
"We are pleased to partner with King Faisal Specialist Hospital and Research Centre to aid in the expansion of its newborn screening program," said Robert F. Friel, President and Chief Operating Officer, PerkinElmer, Inc. "PerkinElmer is committed to supporting early detection programs worldwide with leading neonatal screening technology designed to identify infants at risk for devastating metabolic disorders, enabling early intervention and treatment to save lives and improve quality of life."
As part of this agreement, the King Faisal Hospital will use Specimen Gate®, PerkinElmer's screening laboratory information management system (LIMS). This software will allow the hospital to implement a comprehensive solution that will electronically track laboratory workflow from sample receipt and preparation, through the analytical steps, to quality control review, reporting and follow-up.
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE